HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bunschoten, H. Articles by Osterhaus, A. D. M. E. Search for Related Content PubMed PubMed Citation Articles by Bunschoten, H. Articles by Osterhaus, A. D. M. E. Agricola Articles by Bunschoten, H. Articles by Osterhaus, A. D. M. E.

Characterization of a New Virus-neutralizing Epitope that Denotes a Sequential Determinant on the Rabies Virus Glycoprotein

¹ National Institute of Public Health and Environmental Protection, P.O. Box 1, 3720 BA Bilthoven, The Netherlands
and² The Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania 19104-4268, U.S.A.

Two new monoclonal antibodies (MAbs) derived from mice immunized with the Pitman-Moore (PM) strain of rabies virus were used to identify and characterize two unique antigenic determinants on the rabies virus glycoprotein. One of the determinants, which defined an additional antigenic site on the rabies virus glycoprotein, was delineated as a distinct epitope by the newly generated MAb, 6-15C4, in competitive binding studies and by comparative antigenic analysis of neutralization-resistant variant viruses. Both antigenic determinants were compared with the five previously described antigenic sites which bind virus-neutralizing antibodies on the challenge virus standard (CVS) and Evelyn-Rokitnicki-Abelseth (ERA) strain glycoproteins. The results presented in this communication show that the 6-15C4 epitope is the first epitope described in the rabies virus glycoprotein that does not depend on the native conformation of the glycoprotein for binding virus-neutralizing antibody. These data suggest that it may be possible to generate a synthetic peptide vaccine against rabies.

Keywords: rabies virus, neutralizing epitope, glycoprotein

Received 6 April 1988; accepted 20 October 1988.

This article has been cited by other articles:

				W. E. Marissen, R. A. Kramer, A. Rice, W. C. Weldon, M. Niezgoda, M. Faber, J. W. Slootstra, R. H. Meloen, M. Clijsters-van der Horst, T. J. Visser, et al. Novel Rabies Virus-Neutralizing Epitope Recognized by Human Monoclonal Antibody: Fine Mapping and Escape Mutant Analysis J. Virol., April 15, 2005; 79(8): 4672 - 4678. [Abstract] [Full Text] [PDF]

				C. Prehaud, S. Lay, B. Dietzschold, and M. Lafon Glycoprotein of Nonpathogenic Rabies Viruses Is a Key Determinant of Human Cell Apoptosis J. Virol., October 1, 2003; 77(19): 10537 - 10547. [Abstract] [Full Text] [PDF]

				N. Johnson, K. L. Mansfield, and A. R. Fooks Canine vaccine recipients recognize an immunodominant region of the rabies virus glycoprotein J. Gen. Virol., November 1, 2002; 83(11): 2663 - 2669. [Abstract] [Full Text] [PDF]